CARPRIEVE 50 MG TABLETS FOR DOGS
Nchi: Ayalandi
Lugha: Kiingereza
Chanzo: HPRA (Health Products Regulatory Authority)
Tabia za bidhaa
(SPC)
13-12-2014
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
CARPROFEN
Inapatikana kutoka:
Norbrook Laboratories Limited
ATC kanuni:
QM01AE91
INN (Jina la Kimataifa):
CARPROFEN
Kipimo:
50 mg/tablet
Dawa fomu:
Tablets
Dawa ya aina:
POM
Kundi la matibabu:
Canine
Eneo la matibabu:
Carprofen
Matibabu dalili:
N.S.A.I.D
Idhini hali ya:
Authorised
Idhini ya tarehe:
2003-07-25
Tabia za bidhaa
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Carprieve 50 mg Tablets for Dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
_ACTIVE SUBSTANCE:_
Carprofen
50 mg
_EXCIPIENTS:_
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Tablets:
A white/off white circular tablet with a break line on one face and "50" scored on the opposing face.
The tablets can be divided into equal halves.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For analgesia and reduction of chronic inflammation in musculoskeletal disturbances in dogs, for example in
degenerative joint disease.
4.3 CONTRAINDICATIONS
Use of this product in cats is contra-indicated.
Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal
ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Refer to statements under Sections 4.3 and 4.5
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 28/11/2014_
_CRN 7019477_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS:
Use in dogs less than 6 weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided,
such dogs may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with
bacterial infection, appropriate concurren
Soma hati kamili
